07/22 Taiwan BIO Weekly
2026-07-22 |
| Taiwan BIO Weekly - Coming soon: 'BIO Asia-Taiwan 2026 Special Edition Newsletter' |
| NTUH-linked study shows how lung cancer uses nerves to weaken immunity 8 July, 2026 An international research team with Taiwanese participation has identified a previously unknown mechanism by which lung cancer activates sensory nerves to weaken the body's immune response, a finding that could offer a new path for cancer treatment. The study "uncovered a neuro-immune regulatory mechanism in lung cancer" and could lead to a new cancer treatment direction based on "cutting off the electricity" to tumors, said Chen Jin-shing, head of National Taiwan University Hospital's (NTUH) Department of Surgery, referring to blocking nerve signals that help cancer grow. More... |
| TaiMed Biologics Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan Press release 8 July, 2026 TaiMed Biologics (TW: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; Trogarzo Injection) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. (TW: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking the final step toward the commercial launch of Trogarzo in Taiwan. More... |
| Honeybear Biosciences Bringing Total Funds Raised to $34 Million to Accelerate Lead Radiopharmaceutical Candidates into Clinical Trial Sponsored article in Endpoints News 6 July, 2026 Honeybear Biosciences Inc. announces the completion of a US$20 million Series A financing round, bringing the total capital raised to US$34 million, making it one of Taiwan's most notable fundraising examples in the next-generation nuclear medicine and precision oncology sectors in recent years. The newly raised capital will primarily support the development of Honeybear's Antibody-Radionuclide Conjugate (ARC) therapeutics into international clinical trials, further strengthening the company's competitive position in the global next-generation precision cancer therapeutics market. More... |
| Startup Island TAIWAN-Led Delegation Secures More Than 100 Business Meetings at BIO 2026, Expanding Global Opportunities for Taiwanese Biotech Startups Press release 3 July, 2026 Six Taiwanese biomedical startups held more than 100 one-on-one business meetings with global pharmaceutical companies, investors, industry partners and research organizations at the BIO International Convention 2026, held from June 22 to 25 in San Diego, California, creating new opportunities for strategic partnerships, technology commercialization and international market expansion. More... |
| PharmaEssentia secures Canadian approval for Ropeg, strengthening North American commercial expansion 3 July, 2026 PharmaEssentia (TW: 6446) announced that its novel drug Ropeginterferon alfa-2b (Ropeg) has received approval from Health Canada for the treatment of polycythemia vera (PV), with commercial launch expected within weeks. Following US approval for PV in 2021, the Canadian approval further strengthens PharmaEssentia's North American market presence. More... (in Chinese) |
| Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations Press release 2 July, 2026 Bora Pharmaceuticals Co., Ltd. (TW: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US$122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics. More... |
| Obigen Pharma's novel botulinum toxin therapy Phase III trial set for year-end data readout 2 July, 2026 Obigen Pharma (TW: 7876), Taiwan's first botulinum toxin drug developer, is advancing its novel 760 kDa long-acting botulinum toxin candidate OBI-858 through Phase III trials. The company said it expects to complete the trial process in Q3 2026 and aims to achieve clinical data unblinding by year-end. A regulatory submission is planned for the first half of 2027, with potential Taiwan commercialization in 2028. More... (in Chinese) |
| Genomics BioSci & Tech subsidiary Lightest Biomedical lands investment from Mosaic Venture Lab, National Development Fund 1 July, 2026 Genomics BioSci & Tech (TW: 4195) announced that its innovative drug development subsidiary, Lightest Biomedical, has successfully completed a seed funding round. The round was led by international venture accelerator Mosaic Venture Lab, with co-investment from Taiwan's National Development Fund under the strategic guidance of the Small and Medium Enterprise and Startup Administration (SMESA), Ministry of Economic Affairs, and the Chinese National Association of Industry and Commerce, Taiwan (CNAIC). More... (in Chinese) |
| San Fu Chemical's biotech expansion gains traction as BioPhoenix advances clinical programs, aims for stock listing by year-end 1 July, 2026 San Fu Chemical (TW: 4755) reported progress in its biotechnology strategy through its investment in San Fu spinoff BioPhoenix. The company's bone marrow transplant new drug is advancing as planned in clinical trials in the US and China. BioPhoenix plans a simplified public offering in the second half of the year and aims to complete Emerging Stock Board listing in Taiwan by year-end. More... (in Chinese) |
| EirGenix signs licensing agreement with Japanese company for breast cancer drug 30 June, 2026 EirGenix (TW: 6589) announced that it has signed a licensing and commercialization agreement with a leading Japanese pharmaceutical company for its HER2-positive breast cancer biosimilar EG1206A, which references Roche's Perjeta. The deal covers the Japan market and is expected to generate up to about NT$1.32 billion in potential value. This follows an earlier global exclusive agreement signed in 2025 with Sandoz AG for markets outside Taiwan, China, and 11 other Asian countries, further expanding EG1206A's international commercialization reach. More... (in Chinese) |
| Lotus Pharmaceuticals receives US FDA approval for new generic drug 30 June, 2026 Lotus Pharmaceuticals (TW: 1795) announced that its US subsidiary Norwich has received FDA approval for its generic Baloxavir Marboxil tablets, becoming the first approved generic version of Roche's influenza drug Xofluza, with analysts noting that its First-to-File status could help expand the company's US market presence and support growth in its specialty generics portfolio. More... (in Chinese) |
| Gongwin Biopharm fat ablation product wins European patent, targets global aesthetic medicine market 30 June, 2026 Gongwin Biopharm (TW: 6617) announced on 30th of June that its subsidiary Taiwan Gongwin has received notification from the European Patent Office granting a European patent for its self-developed fat ablation product, which contains a composition involving p-toluenesulfonamide (PTS). This milestone in intellectual property represents a key legal and commercial protective barrier for Gongwin Biopharm's planned expansion into Europe and the global aesthetic medicine market, while also underscoring the international market value of its patented technology platform. More... (in Chinese) |
| Ever Supreme Bio Technology advances new drug into Phase II clinical trials 29 June, 2026 Ever Supreme Bio Technology (TW: 6712) announced that its allogeneic, off-the-shelf CAR-T cancer therapy CAR001 has completed Phase I clinical trials and received approval from Taiwan's Safety Monitoring Committee to proceed to a Phase IIa study. The company plans to use Phase IIa results to support a future global multi-country, multi-center trial strategy and is also seeking international licensing or co-development partnerships to accelerate CAR001's development for solid tumor treatment and expand global commercialization opportunities. More... (in Chinese) |
| TAHO Pharmaceuticals targets September TWSE Listing, expects drug licensing deal before debut 28 June, 2026 TAHO Pharmaceuticals (TW: 6467) said on June 28 that its 505(b)(2) oral dissolving antithrombotic film, TAH3311, is on track to obtain European marketing authorization in the fourth quarter of this year, while US approval could follow in the second quarter of next year. The company also expects to complete one or two drug licensing agreements before transferring from Taiwan's Emerging Stock Market to the TWSE in September. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |